FR2215416A1 - - Google Patents

Info

Publication number
FR2215416A1
FR2215416A1 FR7302991A FR7302991A FR2215416A1 FR 2215416 A1 FR2215416 A1 FR 2215416A1 FR 7302991 A FR7302991 A FR 7302991A FR 7302991 A FR7302991 A FR 7302991A FR 2215416 A1 FR2215416 A1 FR 2215416A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7302991A
Other languages
French (fr)
Other versions
FR2215416B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR7302991A priority Critical patent/FR2215416B1/fr
Priority to US433569A priority patent/US3872092A/en
Priority to CA190,884A priority patent/CA1037025A/fr
Priority to JP49010334A priority patent/JPS5826359B2/ja
Priority to BE140249A priority patent/BE810249A/xx
Priority to LU69253A priority patent/LU69253A1/xx
Priority to CH113674A priority patent/CH591515A5/xx
Priority to NL7401106A priority patent/NL7401106A/xx
Priority to DE2404130A priority patent/DE2404130A1/de
Priority to DK45174AA priority patent/DK137928B/da
Priority to GB400574A priority patent/GB1424302A/en
Priority to IE170/74A priority patent/IE38805B1/xx
Publication of FR2215416A1 publication Critical patent/FR2215416A1/fr
Application granted granted Critical
Publication of FR2215416B1 publication Critical patent/FR2215416B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR7302991A 1973-01-29 1973-01-29 Expired FR2215416B1 (enExample)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR7302991A FR2215416B1 (enExample) 1973-01-29 1973-01-29
US433569A US3872092A (en) 1973-01-29 1974-01-15 Novel {66 {hu 9,11{b -Gonadiene-5{60 -ols
CA190,884A CA1037025A (fr) 1973-01-29 1974-01-24 Procede de preparation de nouveaux derives steroides 5.alpha.-hydroxy 13.beta.-alcoyl gona 9,11-dieniques
JP49010334A JPS5826359B2 (ja) 1973-01-29 1974-01-25 ゴナトリエンカゴウブツノセイゾウホウ
LU69253A LU69253A1 (enExample) 1973-01-29 1974-01-28
CH113674A CH591515A5 (enExample) 1973-01-29 1974-01-28
BE140249A BE810249A (fr) 1973-01-29 1974-01-28 Nouveaux 5 alpha-hydroxy gonadienes
NL7401106A NL7401106A (enExample) 1973-01-29 1974-01-28
DE2404130A DE2404130A1 (de) 1973-01-29 1974-01-29 5 alpha-hydroxy-gona-9,11-diene, verfahren zu deren herstellung und deren verwendung zur herstellung von triensteroiden
DK45174AA DK137928B (da) 1973-01-29 1974-01-29 Fremgangsmåde til fremstilling af 5alfa-hydroxygona-9,11-diener.
GB400574A GB1424302A (en) 1973-01-29 1974-01-29 5alpha-hydroxy-gona-9,11-dienes and processes for their preparation
IE170/74A IE38805B1 (en) 1973-01-29 1974-01-29 5a-hydroxy-gona-9,11-dienes, and processes for their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7302991A FR2215416B1 (enExample) 1973-01-29 1973-01-29

Publications (2)

Publication Number Publication Date
FR2215416A1 true FR2215416A1 (enExample) 1974-08-23
FR2215416B1 FR2215416B1 (enExample) 1976-09-10

Family

ID=9113975

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7302991A Expired FR2215416B1 (enExample) 1973-01-29 1973-01-29

Country Status (12)

Country Link
US (1) US3872092A (enExample)
JP (1) JPS5826359B2 (enExample)
BE (1) BE810249A (enExample)
CA (1) CA1037025A (enExample)
CH (1) CH591515A5 (enExample)
DE (1) DE2404130A1 (enExample)
DK (1) DK137928B (enExample)
FR (1) FR2215416B1 (enExample)
GB (1) GB1424302A (enExample)
IE (1) IE38805B1 (enExample)
LU (1) LU69253A1 (enExample)
NL (1) NL7401106A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006819A1 (de) * 1992-09-22 1994-03-31 Schering Aktiengesellschaft Gestagen wirksame 4,5;11,12-estradiene, verfahren zu ihrer herstellung, diese estradiene enthaltende arzneimittel sowie deren verwendung zur herstellung von arzneimitteln
WO1996030390A3 (en) * 1995-03-30 1997-01-09 Us Health METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES.

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL51468A (en) * 1976-02-23 1981-01-30 Sparamedica Ag 17 -hydroxy- -d-homosteroid derivatives,their preparation and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006819A1 (de) * 1992-09-22 1994-03-31 Schering Aktiengesellschaft Gestagen wirksame 4,5;11,12-estradiene, verfahren zu ihrer herstellung, diese estradiene enthaltende arzneimittel sowie deren verwendung zur herstellung von arzneimitteln
WO1996030390A3 (en) * 1995-03-30 1997-01-09 Us Health METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES.
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates

Also Published As

Publication number Publication date
IE38805B1 (en) 1978-06-07
GB1424302A (en) 1976-02-11
CA1037025A (fr) 1978-08-22
LU69253A1 (enExample) 1974-09-25
DE2404130A1 (de) 1974-08-01
FR2215416B1 (enExample) 1976-09-10
DK137928C (enExample) 1978-10-30
IE38805L (en) 1974-07-29
US3872092A (en) 1975-03-18
CH591515A5 (enExample) 1977-09-30
NL7401106A (enExample) 1974-07-31
BE810249A (fr) 1974-07-29
JPS5826359B2 (ja) 1983-06-02
JPS5046655A (enExample) 1975-04-25
DK137928B (da) 1978-06-05

Similar Documents

Publication Publication Date Title
AU476761B2 (enExample)
AU474593B2 (enExample)
AU474511B2 (enExample)
AU474838B2 (enExample)
AU471343B2 (enExample)
AU476714B2 (enExample)
AU472848B2 (enExample)
AU476696B2 (enExample)
FR2215416B1 (enExample)
AU477823B2 (enExample)
AU477824B2 (enExample)
AU471461B2 (enExample)
AR201432A1 (enExample)
AU476873B1 (enExample)
BG18461A1 (enExample)
AU479419A (enExample)
CH1744873A4 (enExample)
CH1363173A4 (enExample)
BG19992A1 (enExample)
BG19217A2 (enExample)
BG18779A1 (enExample)
AU479522A (enExample)
BG18244A1 (enExample)
AU479539A (enExample)
AU479521A (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse